News

Strategic Partnership
11.05.2021

Helmholtz Zentrum München and Novo Nordisk extended their research collaboration in metabolic diseases

Helmholtz Zentrum München and Novo Nordisk recently extended their multi-year strategic partnership which aims to identify and jointly develop novel targets and enabling technologies, ultimately supporting the development of innovative medicines for metabolic diseases.

©SFIO CRACHO - stock.adobe.com

The collaboration leverages the scientific knowledge, expertise and translational research capabilities of Helmholtz Zentrum München researchers and Novo Nordisk’s extensive know-how within research, clinical development and commercialization of pharmaceutical products against chronic metabolic diseases.